<DOC>
	<DOCNO>NCT01964755</DOCNO>
	<brief_summary>By combine variety agent potentiate Zidovudine ( ZDV ) , investigator hope induce remission generally fatal disease . Most therapy aggressive B cell lymphoma base upon intensive chemotherapeutic regimen , expensive modality ( bone marrow transplant , Rituximab ) , experimental approach ( gene therapy , cytotoxic T cell infusion ) difficult implement heavily pre-treated patient . Therapy relapse aggressive B cell lymphoma poor . Even curable lymphoma Burkitt Lymphoma ( BL ) Hodgkin lymphoma extremely difficult treat relapse and/or stem cell transplant failure . The investigator propose novel therapeutic approach exploit presence Epstein-Barr virus ( EBV ) lymphoma ; antiviral mediate suppression NF-kB disruption viral latency .</brief_summary>
	<brief_title>Phase II Chemotherapy Relapsed Epstein Barr Virus Associated Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Virus Diseases</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Hydroxyurea</mesh_term>
	<mesh_term>Zidovudine</mesh_term>
	<mesh_term>Antiviral Agents</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Formyltetrahydrofolates</mesh_term>
	<mesh_term>Tetrahydrofolates</mesh_term>
	<criteria>1 . Any stage , histologically cytologically document intermediate high grade relapse refractory EBV+ nonHodgkin 's ( NHL ) Hodgkin 's lymphoma ( HL ) , treat untreated patient EBV+ lymphoma involve CNS . Patients relapse refractory monomorphic ( monoclonal ) posttransplant lymphoproliferative disease ( PTLD ) also eligible . 2 . Patients HIV+ negative . Documentation HIV infection do time prior study entry . Documentation may serologic ( positive ELISA positive Western blot ) , molecular ( positive HIV viral RNA ) , federally approve licensed HIV test . Prior documentation HIV seropositivity acceptable . 3 . Tumors must positive EBV . This may do either EpsteinBarr virusencoded small RNA ( EBER ) stain original tumor biopsy relapse disease ( perform ) . Biopsy relapse disease desirable mandatory . If stain EpsteinBarr virus latent membrane protein 1 ( LMP1 ) do outside positive , EBER need do . 4 . All patient , except CNS involvement , must relapse progress least one previous chemotherapy base regimen . 5 . Measurable nonmeasurable tumor parameter ( ) . Nonmeasurable tumor parameter ( ) define bidimensional measurement ( e.g. , gastric marrow involvement ) , follow response diagnostic test gallium scan , Positron emission tomography ( PET ) image and/or bone marrow biopsy . 6 . Age ≥ 18 year . 7 . Karnofsky performance status ( KPS ) ≥ 50 % /Eastern Cooperative Oncology Group ( ECOG ) Performance Score 0 , 1 , 2 . 8 . Patients must adequate end organ bone marrow function define : 8.1 Absolute neutrophil count ≥ 1,500 cells/mm3 platelet ≥ 75,000 cells/dL unless cytopenias secondary lymphomatous involvement bone marrow due HIVrelated thrombocytopenia . All patient must colony stimulate factor therapy least 24 hour prior institution Cycle 1 chemotherapy . 8.2 Adequate hepatic function : Serum glutamicoxaloacetic transaminase ( SGOT ) ≤ 5 time upper limit normal . Total bilirubin ≤ 2.0 mg/dL ( unless elevate secondary lymphomatous involvement liver biliary system due HIV medication [ e.g. , indinavir , tenofovir atazanavir ] ) . Patients negative Hepatitis B , infect Hepatitis B , receive antiHepatitis B therapy eligible . All subject require screen Hepatitis B C. Per Infectious Diseases Society America ( IDSA ) American Association Study Liver Diseases ( AASD ) guideline , subject show immunity , define lack Hepatitis B surface antibody , show evidence chronic infection ( i.e . HBsAg+ , HBcore+ , HBsAB ) require antiHepatitis B therapy , study , order eligible . Patients permit enroll study provide liver function test meet criterion list , evidence cirrhosis . The exact Hepatitis B therapy discretion infection disease specialist investigator . However patient present acute hepatitis B show normal transaminase HBsAg+ IgM+ Hepatitis core antigen eligible trial enrollment . Subjects Hepatitis C antibody positive , without positive Hepatitis C RNA level , permit enroll study provide liver function test meet criterion list , evidence cirrhosis . Patients diagnose Hepatitis C le 6 month trial enrollment , consider Acute Hepatitis C exclude study unless Hep C viral load undetectable . 8.3 Creatinine ≤ 2.0 mg/dL creatinine clearance ≥ 60 mL/min unless due renal involvement lymphoma . 9 . Concurrent radiation , without steroid , emergency condition secondary lymphoma ( CNS tumor , cord compression , etc . ) permit . 10 . Females childbearing potential must negative serum pregnancy test within 7 day prior enter study . Men woman must agree use adequate birth control conception possible study . Women must avoid pregnancy men avoid father child study 6 month follow last study drug treatment . 11 . Able give consent . 12 . Patients already receive erythropoietin Granulocytecolony stimulating factor ( GCSF ) eligible , although GCSF therapy must discontinue least 24 hour prior receive chemotherapy . 13 . The maximum cumulative dose doxorubicin allow 450 mg/m2 . Patients previously receive doxorubicin cumulative dose 350 mg/m2 great eligible MAY NOT receive doxorubicin protocol . 1 . Concurrent active malignancy , exception situ carcinoma cervix , nonmetastatic , nonmelanomatous skin cancer , Kaposi sarcoma require systemic chemotherapy . 2 . Myocardial infarction ( MI ) within 6 month prior study entry , New York Heart Association ( NYHA ) Class II great heart failure , uncontrolled angina , severe , uncontrolled ventricular arrhythmia , clinically significant pericardial disease , electrocardiograph evidence acute ischemic active conduction system abnormality . 3 . Left Ventricular Ejection Fraction ( LVEF ) less low institutional limit normal assessed Multiple Gated Acquisition ( MUGA ) scan echocardiogram within 6 week prior registration . 4 . Subjects viral hepatitis meet criterion list ( 8.2 ) eligible . All patient present acute hepatitis B include normal transaminase HBsAg+ IgM + hepatitis core antigen eligible . Subjects Hepatitis B core antibody positive eligible start prophylactic therapy . A hepatitis B viral load confirm negative patient hepatitis B core antibody positive , hepatitis B antigen negative . Patients refuse take antihepatitis B therapy study also exclude . Patients diagnose Hepatitis C eligible meet criterion list ( 8.2 ) . 5 . Psychological , familial , sociological geographical condition permit treatment and/or medical followup require comply study protocol . 6 . Patients may receive investigational agent . 7 . Uncontrolled intercurrent illness include , limited , ongoing active infection , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , psychiatric illness/social situation would limit compliance study requirement . Patients mycobacterium avium exclude . 8 . Pregnant breastfeed woman .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>EBV+</keyword>
	<keyword>NHL</keyword>
	<keyword>HL</keyword>
	<keyword>Non Hodgkin 's Lymphoma</keyword>
	<keyword>Hodgkin 's Lymphoma</keyword>
	<keyword>Epstein Barr Virus</keyword>
	<keyword>Epstein Barr Virus Associated Non Hodgkin 's Lymphoma</keyword>
	<keyword>Epstein Barr Virus Associated Hodgkin 's Lymphoma</keyword>
	<keyword>Post-Transplant Lymphoproliferative Disease</keyword>
</DOC>